Browsing Tag
pre|CISION platform
5 posts
Avacta Therapeutics (AIM: AVCT) secures FDA clearance for AVA6103 as pre|CISION platform enters its second clinical test
Avacta Therapeutics secures FDA IND clearance for AVA6103, advancing its pre|CISION platform into a second clinical program. Read what changes next.
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
Can Avacta’s peptide drug conjugates rival ADCs? The next chapter in targeted cancer delivery
Avacta’s peptide drug conjugates could change how we deliver cancer drugs. Find out how they compare to ADCs and what’s next for the UK biotech’s platform.
Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?
Avacta completes sale of Coris Bioconcept to focus solely on oncology. Find out what this pivot means for its stock, strategy, and pre|CISION® pipeline.